Article
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial - Nature Medicine
Rating:
0.0
Views:
18
Likes:
1
Library:
1
Individuals with kidney failure undergoing hemodialysis are at elevated risk for thromboembolic events. Factor (F) XI, which is in the intrinsic pathway of coagulation, is emerging as an attractive target for new anticoagulants that may be safer than existing agents. Osocimab—an inhibitory FXIa antibody—is a potential treatment option for such patients.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value